AbbVie Inc.

NYSE:ABBV Stock Report

Market Cap: US$405.3b

AbbVie Management

Management criteria checks 2/4

AbbVie's CEO is Robert Michael, appointed in Jul 2024, has a tenure of 1.5 years. total yearly compensation is $18.49M, comprised of 8.7% salary and 91.3% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth $30.48M. The average tenure of the management team and the board of directors is 2.1 years and 9.3 years respectively.

Key information

Robert Michael

Chief executive officer

US$18.5m

Total compensation

CEO salary percentage8.69%
CEO tenure1.5yrs
CEO ownership0.008%
Management average tenure2.1yrs
Board average tenure9.3yrs

Recent management updates

Recent updates

AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026

Jan 02

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73

Dec 02
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

Nov 18
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear

May 16
AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear

AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside

Apr 25

AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)

Apr 09

AbbVie Vs. Sanofi: Which Is The Better Investment Right Now

Mar 28

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk

Mar 13

Investors Don't See Light At End Of AbbVie Inc.'s (NYSE:ABBV) Tunnel

Feb 25
Investors Don't See Light At End Of AbbVie Inc.'s (NYSE:ABBV) Tunnel

Why AbbVie Remains A Strong Buy For Long-Term Investors

Feb 23

CEO Compensation Analysis

How has Robert Michael's remuneration changed compared to AbbVie's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

US$2b

Jun 30 2025n/an/a

US$4b

Mar 31 2025n/an/a

US$4b

Dec 31 2024US$18mUS$2m

US$4b

Sep 30 2024n/an/a

US$5b

Jun 30 2024n/an/a

US$5b

Mar 31 2024n/an/a

US$6b

Dec 31 2023US$14mUS$1m

US$5b

Sep 30 2023n/an/a

US$6b

Jun 30 2023n/an/a

US$9b

Mar 31 2023n/an/a

US$8b

Dec 31 2022US$10mUS$1m

US$12b

Sep 30 2022n/an/a

US$13b

Jun 30 2022n/an/a

US$13b

Mar 31 2022n/an/a

US$12b

Dec 31 2021US$12mUS$1m

US$11b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$7b

Mar 31 2021n/an/a

US$5b

Dec 31 2020US$13mUS$1m

US$5b

Sep 30 2020n/an/a

US$7b

Jun 30 2020n/an/a

US$7b

Mar 31 2020n/an/a

US$8b

Dec 31 2019US$9mUS$907k

US$8b

Compensation vs Market: Robert's total compensation ($USD18.49M) is above average for companies of similar size in the US market ($USD13.45M).

Compensation vs Earnings: Robert's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Robert Michael (55 yo)

1.5yrs
Tenure
US$18,492,517
Compensation

Mr. Robert A. Michael served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as its CEO and...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Michael
CEO & Chairman of the Board1.5yrsUS$18.49m0.0075%
$ 30.5m
Scott Reents
Executive VP & CFO3.6yrsUS$10.99m0.00066%
$ 2.7m
Azita Saleki-Gerhardt
Executive VP & COO1.5yrsUS$9.92m0.010%
$ 42.1m
Jeffrey Stewart
Executive VP & Chief Commercial Officerno dataUS$14.05m0.0031%
$ 12.5m
Roopal Thakkar
Executive VP of Research and Development & Chief Scientific Officer1.5yrsno data0.0024%
$ 9.7m
Elizabeth Shea
Senior Vice President of Investor Relationsno datano datano data
Perry Siatis
Executive VP3.3yrsno data0.00026%
$ 1.1m
Demetris Crum
Executive VP & Chief Human Resources Officer1yrno data0.00034%
$ 1.4m
Wulff-Erik von Borcke
Senior VP & President of Oncology2.3yrsno datano data
Nicholas Donoghoe
Executive VP and Chief Business & Strategy Officer3yrsno data0.0033%
$ 13.4m
Tracie Haas
Senior Vice President of Corporate Affairs2yrsno datano data
Latif Akintade
Senior Vice President of Medical Affairs & Health Economics Outcomes Research2.3yrsno datano data
2.1yrs
Average Tenure
55yo
Average Age

Experienced Management: ABBV's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Michael
CEO & Chairman of the Board1.5yrsUS$18.49m0.0075%
$ 30.5m
Roxanne Austin
Lead Independent Director13yrsUS$456.67k0.00065%
$ 2.6m
Thomas Freyman
Independent Director5.7yrsUS$382.32k0.0071%
$ 28.7m
Edward Rapp
Independent Director13yrsUS$405.47k0.00090%
$ 3.6m
William H. Burnside
Independent Director13yrsUS$369.82kno data
Frederick Waddell
Independent Director13yrsUS$410.25k0.00011%
$ 445.8k
Melody Meyer
Independent Director8.7yrsUS$404.70k0%
$ 0
Brett Hart
Independent Director10yrsUS$384.82kno data
Rebecca Roberts
Independent Director7.7yrsUS$378.55kno data
Robert Alpern
Independent Director13yrsUS$525.48k0.000010%
$ 40.5k
Susan Quaggin
Independent Director2.3yrsUS$351.92k0%
$ 0
Jennifer Davis
Independent Director2.3yrsUS$359.82k0.000070%
$ 283.7k
9.3yrs
Average Tenure
67.5yo
Average Age

Experienced Board: ABBV's board of directors are considered experienced (9.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/04 01:40
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AbbVie Inc. is covered by 53 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Luisa HectorBerenberg
Timothy AndersonBernstein